By Dr Louise Emmett

Journal articles

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID, 2024, '[¹⁷⁷Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial', The Lancet Oncology, 25, pp. 563 - 571, http://dx.doi.org/10.1016/S1470-2045(24)00135-9

Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Koerber SA; Debus J; Peeken JC; Vogel MME; Kroeze SGC; Guckenberger M; Krafcsik M; Hruby G; Emmett L; Schmidt-Hegemann NS; Trapp C; Spohn SKB; Henkenberens C; Mayer B; Shelan M; Aebersold DM; Thamm R; Wiegel T, 2024, 'European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy', Radiotherapy and Oncology, 194, http://dx.doi.org/10.1016/j.radonc.2024.110215

Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L, 2024, 'Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes.', J Nucl Med, http://dx.doi.org/10.2967/jnumed.123.267014

Gafita A; Martin AJ; Emmett L; Eiber M; Iravani A; Fendler WP; Buteau J; Sandhu S; Azad AA; Herrmann K; Stockler MR; Davis ID; Hofman MS, 2024, 'Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial.', Eur Urol Oncol, http://dx.doi.org/10.1016/j.euo.2024.03.009

Geboers B; Meijer D; Counter W; Blazevski A; Thompson J; Doan P; Gondoputro W; Katelaris A; Haynes AM; Delprado W; O'Neill G; Yuen C; Vis AN; van Leeuwen PJ; Ho B; Liu V; Lee J; Donswijk ML; Oprea-Lager D; Scheltema MJ; Emmett L; Stricker PD, 2024, 'Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy', BJU International, 133, pp. 14 - 22, http://dx.doi.org/10.1111/bju.16207

Geboers B; Scheltema MJV; Emmett L; Stricker PD, 2024, 'Reply to ‘Re: Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy’', BJU International, 133, pp. 25 - 26, http://dx.doi.org/10.1111/bju.16308

Kumar S; Crumbaker M; Emmett L, 2024, '“Unraveling the Hypocalcemic Response to ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy,”', Journal of Nuclear Medicine, 65, pp. 333 - 334, http://dx.doi.org/10.2967/jnumed.123.266768

Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RDA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L, 2024, 'The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy', BJU International, 133, pp. 39 - 47, http://dx.doi.org/10.1111/bju.16158

Oprea-Lager DE; MacLennan S; Bjartell A; Briganti A; Burger IA; de Jong I; De Santis M; Eberlein U; Emmett L; Fizazi K; Gillessen S; Herrmann K; Heskamp S; Iagaru A; Jereczek-Fossa BA; Kunikowska J; Lam M; Nanni C; O'Sullivan JM; Panebianco V; Sala E; Sathekge M; Sosnowski R; Tilki D; Tombal B; Treglia G; Tunariu N; Walz J; Yakar D; Dierckx R; Sartor O; Fanti S, 2024, 'European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer', European Urology, 85, pp. 49 - 60, http://dx.doi.org/10.1016/j.eururo.2023.09.003

Swiha M; Ayati N; Oprea-Lager DE; Ceci F; Emmett L, 2024, 'How to Report PSMA PET', Seminars in Nuclear Medicine, 54, pp. 14 - 29, http://dx.doi.org/10.1053/j.semnuclmed.2023.07.007

Hofman MS; Emmett L; Sandhu S; Iravani A; Buteau JP; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; Stockler MR; Williams SG; Martin AJ; Davis ID; Akhurst T; Alipour R; Bailey D; Banks P; Beaulieu A; Campbell L; Crumbaker M; Dhiantravan N; Hamid A; Haskali M; Hung T; Kong G; Lawrence N; Lewin J; McCarthy M; Moodie K; Murphy D; Nguyen A; Pook D; Ravi Kumar A; Roach P; Roselt P; Saghebi J; Schembri G; Spain L; Subramaniam S; Thang SP; Thomas P; Tran B; Wallace R; Yip S, 2024, 'Overall survival with [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial', The Lancet Oncology, 25, pp. 99 - 107, http://dx.doi.org/10.1016/S1470-2045(23)00529-6

Ndlovu H; Mokoala KMG; Lawal I; Emmett L; Sathekge MM, 2024, 'Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals', PET Clinics, http://dx.doi.org/10.1016/j.cpet.2024.03.003

Emmett L; Papa N; Counter W; Calais J; Barbato F; Burger I; Eiber M; Roberts MJ; Agrawal S; Franklin A; Xue A; Rasiah K; John N; Moon D; Frydenberg M; Yaxley J; Stricker P; Wong K; Coughlin G; Gianduzzo T; Kua B; Ho B; Nguyen A; Liu V; Lee J; Hsiao E; Sutherland T; Perry E; Fendler WP; Hope TA, 2024, 'Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database', Journal of Nuclear Medicine, 65, http://dx.doi.org/10.2967/jnumed.123.266164

Adebahr S; Althaus A; Scharl S; Strouthos I; Farolfi A; Serani F; Lanzafame H; Trapp C; Koerber SA; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Grosu AL; Kroeze SGC; Guckenberger M; Fanti S; Hruby G; Emmett L; Belka C; Schmidt-Hegemann NS; Henkenberens C; Aebersold DM; Wiegel T; Afshar-Oromieh A; Zamboglou C; Shelan M, 2024, 'The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy', European Journal of Nuclear Medicine and Molecular Imaging, 51, pp. 558 - 567, http://dx.doi.org/10.1007/s00259-023-06438-3

Swiha M; Gafita A; Nguyen A; Emmett L, 2024, 'Treatment Response Imaging in Prostate Cancer', PET Clinics, http://dx.doi.org/10.1016/j.cpet.2024.03.009

Russell M; Emmett L; Peric B; Saw R; Spillane J; Vazquez V; Duprat J; Moncreiff M; Allan C; Leeuwen BV; Pritchard-Jones R; Rastrelli M; de Wilt H; Geh J; Howle J; Spillane A, 2024, 'Accuracy of PET/CT in the diagnosis of pelvic lymph node metastases in melanoma: A subgroup analysis of the evaluation of groin lymphadenectomy extent for metastatic melanoma (EAGLE-FM) trial', European Journal of Surgical Oncology, 50, pp. 107397 - 107397, http://dx.doi.org/10.1016/j.ejso.2023.107397

Emmett L; Papa N; Hope T; Fendler W; Calais J; Burger I; Eiber M; Barbato F; Moon D; Xue A; Franklin A; Thompson J; Rasiah K; Frydenberg M; Yaxley J; Buteau J; Liu V; Nguyen A; Hsiao E; Stricker P; Hofman M; Kasivisvanathan V; Roberts M; Murphy D, 2024, 'Combining MRI PI-RADS and PSMA-PET/CT PRIMARY score in a composite (P) score for more accurate diagnosis of clinically significant prostate cancer', European Urology, 85, pp. S476 - S476, http://dx.doi.org/10.1016/s0302-2838(24)00417-2

Vis A; Meijer D; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; Van Der Ven PM; Heymans MW; Nieuwenhuijzen JA; Van Der Poel HG; Van Donswijk ML; Boellaard TN; Schoots IG; Stricker P; Haynes A-M; Oprea-Lager DE; Coughlin GD; Van Leeuwen PJ, 2024, 'Development and external validation of a novel nomogram to predict the probability of pelvic lymph-node metastases in prostate cancer patients using magnetic resonance imaging and molecular imaging with prostate-specific membrane antigen positron emission', European Urology, 85, pp. S483 - S484, http://dx.doi.org/10.1016/s0302-2838(24)00422-6

Van Leeuwen PJ; Berrens A-C; Vis A; Yaxley J; Meijer D; Siriwardana A; Wit E; Van Der Noort V; Morton A; Franklin A; Yaxley J; Wong D; Goughlin G; Gianduzzo T; Kua B; Emmett L; Zuur L; Van Der Poel H; Roberts M, 2024, 'The early oncological effect of extended pelvic lymph node dissection in men with at PSMA PET/CT N0M0 intermediate/high-risk prostate cancer - an international cohort study', European Urology, 85, pp. S1263 - S1264, http://dx.doi.org/10.1016/s0302-2838(24)01002-9

Buteau JP; Moon D; Fahey MT; Roberts MJ; Thompson J; Murphy DG; Papa N; Mitchell C; De Abreu Lourenco R; Dhillon HM; Kasivisvanathan V; Francis RJ; Stricker P; Agrawal S; O'Brien J; McVey A; Sharma G; Levy S; Ayati N; Nguyen A; Lee S-F; Pattison DA; Sivaratnam D; Frydenberg M; Du Y; Titus J; Lee S-T; Ischia J; Jack G; Hofman MS; Emmett L, 2023, 'Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer.', Eur Urol Oncol, http://dx.doi.org/10.1016/j.euo.2023.11.008

Vis AN; Meijer D; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; van de Ven PM; Heymans MW; Nieuwenhuijzen JA; van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Stricker P; Haynes AM; Oprea-Lager DE; Coughlin GD; van Leeuwen PJ, 2023, 'Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography', European urology oncology, 6, pp. 553 - 563, http://dx.doi.org/10.1016/j.euo.2023.03.010

Tremblay S; Alhogbani M; Weickhardt A; Davis ID; Scott AM; Hicks RJ; Metser U; Chua S; Davda R; Punwani S; Payne H; Tunariu N; Ho B; Young S; Singbo MNU; Bauman G; Emmett L; Pouliot F, 2023, 'Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial', Cancer Imaging, 23, http://dx.doi.org/10.1186/s40644-023-00570-x

Mohan R; Kneebone A; Eade T; Hsiao E; Emmett L; Brown C; Hunter J; Hruby G, 2023, 'Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer', Radiation Oncology, 18, http://dx.doi.org/10.1186/s13014-023-02302-8

Crumbaker M; Goldstein LD; Murray DH; Tao J; Pathmanandavel S; Boulter N; Ratnayake L; Joshua AM; Kummerfeld S; Emmett L, 2023, 'Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617', European Urology Open Science, 57, pp. 30 - 36, http://dx.doi.org/10.1016/j.euros.2023.08.007

Gondoputro W; Doan P; Katelaris A; Scheltema MJ; Geboers B; Agrawal S; Liu Z; Yaxley J; Savdie R; Rasiah K; Frydenberg M; Roberts MJ; Malouf D; Wong D; Shnier R; Delprado W; Emmett L; Stricker PD; Thompson J, 2023, '⁶⁸Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study', Translational Andrology and Urology, 12, pp. 1598 - 1606, http://dx.doi.org/10.21037/tau-22-708

Pouliot F; Emmett L, 2023, 'Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now', European Urology, 84, pp. 371 - 372, http://dx.doi.org/10.1016/j.eururo.2023.07.007

Kumar S; Crumbaker M; Harvey C; Pathmanandavel S; John N; Swiha MM; McDonald MM; Clifton-Bligh R; Lee A; Bastick P; Counter W; Nguyen A; Emmett L, 2023, 'The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177Lu-Prostate-Specific Membrane Antigen Therapy', Journal of Nuclear Medicine, 64, pp. 1412 - 1416, http://dx.doi.org/10.2967/jnumed.123.265759

Roberts MJ; Hruby G; Kneebone A; Martin JM; Williams SG; Frydenberg M; Murphy DG; Namdarian B; Yaxley JW; Hofman MS; Davis ID; Emmett L, 2023, 'Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky?', BJU International, 132, pp. 146 - 148, http://dx.doi.org/10.1111/bju.16086

Mei R; Kessler L; Pabst KM; Weber M; Schmidkonz C; Rischpler C; Zacho HD; Hope T; Schwarzenbock SM; Allen-Auerbach M; Emmett L; Ferdinandus J; Unterrainer M; Schaarschmidt BM; Umutlu L; Farolfi A; Castellucci P; Nanni C; Telo S; Fanti S; Herrmann K; Fendler WP, 2023, '⁶⁸Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study', Journal of Nuclear Medicine, 64, pp. 1043 - 1048, http://dx.doi.org/10.2967/jnumed.122.265245

Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D, 2023, 'A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy', European Urology Open Science, 53, pp. 90 - 97, http://dx.doi.org/10.1016/j.euros.2023.05.002

Kratochwil C; Fendler WP; Eiber M; Hofman MS; Emmett L; Calais J; Osborne JR; Iravani A; Koo P; Lindenberg L; Baum RP; Bozkurt MF; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen WJG; Rahbar K; Schoder H; Virgolini I; Bodei L; Fanti S; Haberkorn U; Hermann K, 2023, 'Joint EANM/SNMMI procedure guideline for the use of ¹⁷⁷Lu-labeled PSMA-targeted radioligand-therapy (¹⁷⁷Lu-PSMA-RLT)', European Journal of Nuclear Medicine and Molecular Imaging, 50, pp. 2830 - 2845, http://dx.doi.org/10.1007/s00259-023-06255-8

Solomonidou N; Germanou D; Strouthos I; Karagiannis E; Farolfi A; Koerber SA; Debus J; Peeken JC; Vogel ME; Vrachimis A; Spohn SKB; Shelan M; Aebersold D; Grosu AL; Ceci F; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Hruby G; Scharl S; Wiegel T; Bartenstein P; Henkenberens C; Emmett L; Schmidt-Hegemann NS; Ferentinos K; Zamboglou C, 2023, 'PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml', European Journal of Nuclear Medicine and Molecular Imaging, 50, pp. 2529 - 2536, http://dx.doi.org/10.1007/s00259-023-06185-5

Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Lanzafame H; Giuseppe Morganti A; Trapp C; Koerber SA; Debus J; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Ruf J; Grosu AL; Ceci F; Fendler WP; Bartenstein P; Kroeze SGC; Guckenberger M; Krafcsik M; Klopscheck C; Fanti S; Hruby G; Emmett L; Belka C; Stief C; Schmidt-Hegemann NS; Henkenberens C; Mayer B; Miksch J; Shelan M; Aebersold DM; Thamm R; Wiegel T, 2023, 'Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study', Radiotherapy and Oncology, 184, http://dx.doi.org/10.1016/j.radonc.2023.109678

Lengyelova E; Wong V; Lenzo N; Parker M; Emmett L, 2023, '⁶⁴Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer.', Journal of Clinical Oncology, 41, pp. 5039 - 5039, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5039

Hamid A; Gupta S; Keerthikumar S; Pasam A; Crumbaker M; Joshua AM; Lam E; Wenstrup R; Emmett L; Goode DL; Hofman MS; Sandhu S, 2023, 'Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus ¹⁷⁷lutetium-prostate specific membrane antigen-617 (¹⁷⁷Lu-PSMA-617) in the LuPARP trial.', Journal of Clinical Oncology, 41, pp. 5064 - 5064, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5064

Unterrainer L; Farolfi A; Rosar F; Denis CS; Emmett L; de Kouchkovsky I; Hope TA; Hotta M; Gafita A; Djaileb L; Czernin J; Calais J, 2023, 'Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study.', Journal of Clinical Oncology, 41, pp. 5063 - 5063, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5063

Soon YY; Marschner I; Hofman MS; Emmett L; Davis ID; Stockler MR; Martin AJ, 2023, 'Effects of [¹⁷⁷Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis.', Journal of Clinical Oncology, 41, pp. 5045 - 5045, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5045

Feldman DR; Tran B; Emmett L; Hofman MS; Olivier P; Mahammedi H; Galetic I; Pokorska-Bocci A; Bouisset F; Gollmer K; Pavlyuk M; Tauchmanova L; Herrmann K, 2023, 'First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.', Journal of Clinical Oncology, 41, pp. TPS3160 - TPS3160, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps3160

Sandhu S; Joshua AM; Emmett L; Crumbaker M; Bressel M; Huynh R; Banks PD; Wallace R; Hamid A; Inderjeeth AJ; Tran B; Azad A; Alipour R; Kong G; Ravi Kumar A; Saghebi J; Williams S; Akhurst TJ; Hicks RJ; Hofman MS, 2023, 'LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 41, pp. 5005 - 5005, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5005

Zamboglou C; Peeken JC; Janbain A; Katsahian S; Strouthos I; Ferentinos K; Farolfi A; Koerber SA; Debus J; Vogel ME; Combs SE; Vrachimis A; Morganti AG; Spohn SKB; Shelan M; Aebersold DM; Grosu AL; Ceci F; Henkenberens C; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Bartenstein P; Hruby G; Scharl S; Wiegel T; Emmett L; Arnoux A; Schmidt-Hegemann NS, 2023, 'Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer', JAMA network open, 6, pp. e2314748, http://dx.doi.org/10.1001/jamanetworkopen.2023.14748

Seifert R; Emmett L; Rowe SP; Herrmann K; Hadaschik B; Calais J; Giesel FL; Reiter R; Maurer T; Heck M; Gafita A; Morris MJ; Fanti S; Weber WA; Hope TA; Hofman MS; Fendler WP; Eiber M, 2023, 'Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)', European Urology, 83, pp. 405 - 412, http://dx.doi.org/10.1016/j.eururo.2023.02.002

Doan P; Counter W; Papa N; Sheehan-Dare G; Ho B; Lee J; Liu V; Thompson JE; Agrawal S; Roberts MJ; Buteau J; Hofman MS; Moon D; Lawrentschuk N; Murphy D; Stricker PD; Emmett L, 2023, 'Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer', BJU International, 131, pp. 588 - 595, http://dx.doi.org/10.1111/bju.15929

Zamboglou C; Arnoux A; Janbain A; Strouthos I; Farolfi A; Koerber S; Peeken J; Vogel M; Ferentinos K; Shelan M; Grosu AL; Kroeze S; Guckenberger M; Fanti S; Hruby G; Scharl S; Wiegel T; Henkeberens C; Emmett L; Hegemann N-S, 2023, 'Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET–based salvage radiotherapy in recurrent prostate cancer.', Journal of Clinical Oncology, 41, pp. 355 - 355, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.355

Sandhu S; Subramaniam S; Hofman MS; Stockler MR; Martin AJ; Pokorski I; Goh JC; Pattison DA; Dhiantravan N; Gedye C; Rutherford NK; Joshua AM; Tan TH; Kirkwood ID; Lee ST; Weickhardt AJ; Alipour R; Nguyen A; Davis ID; Emmett L, 2023, 'Evolution: Phase II study of radionuclide ¹⁷⁷Lu-PSMA-617 therapy versus ¹⁷⁷Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).', Journal of Clinical Oncology, 41, pp. TPS271 - TPS271, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps271

Tremblay S; Alhogbani M; Weickhardt A; Davis ID; Scott AM; Hicks RJ; Metser U; Chua S; Davda R; Punwani S; Payne HA; Tunariu N; Ho B; Young S; Bauman G; Emmett L; Pouliot F, 2023, 'Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: A post hoc analysis of the PROPS trial.', Journal of Clinical Oncology, 41, pp. 316 - 316, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.316

Gupta S; Hamid A; Fernandez L; Pasam A; Lam E; Tubbs A; Bourdon D; Emmett L; Joshua AM; Hofman MS; Wenstrup R; Sandhu S, 2023, 'Performance of a blood-based liquid biopsy test to detect PSMA expression on circulating tumor cells in men with metastatic prostate cancer.', Journal of Clinical Oncology, 41, pp. 256 - 256, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.256

Emmett L; Wong V; Lenzo N; Lengyelova E; Biggin C, 2023, 'Positron emission tomography of patients with confirmed prostate cancer using ⁶⁴Cu-SAR-bisPSMA.', Journal of Clinical Oncology, 41, pp. 318 - 318, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.318

Buteau JP; Moon D; Fahey MT; Roberts M; Thompson J; Murphy DG; Papa N; Mitchell C; Kasivisvanathan V; Stricker P; O'Brien J; Counter W; Sharma G; Agrawal S; Ho B; Yeung T; De Abreu Lourenço R; Dhillon HM; Hofman MS; Emmett L, 2023, 'PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [⁶⁸Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer.', Journal of Clinical Oncology, 41, pp. TPS397 - TPS397, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps397

Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L, 2023, 'Evaluation of ¹⁷⁷Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective ¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398

John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L, 2023, '¹⁷⁷Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing ¹⁷⁷Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677

Back to profile page